. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675

Table 3.

Symptomatic venous thromboembolism, clinically relevant bleeding, and net clinical endpoint by type of surgery

Variables	No of events/No in group			Relative risk (95%CI)		Weight (%)	P value*
Variables	New anticoagulant	Enoxaparin		Relative risk (95%CI)		Weight (%)	P value*
Symptomatic venous thromboembolism
Dabigatran:
Hip^{20 22}	23/3367	10/2181	0.78 (0.05 to 12.35)			42.5	0.83
Knee^{19 21}	25/3141	19/1575	0.56 (0.16 to 1.98)			57.5	0.83
Rivaroxaban:
Hip^{23 24 27 29 30}	11/3888	27/3990	0.52 (0.18 to 1.45)			35.6	0.93
Knee^{25 26 28}	21/2940	44/2946	0.49 (0.29 to 0.83)			64.4	0.93
Apixaban:
Hip³³	4/2708	10/2699	0.40 (0.13 to 1.27)			23	0.14
Knee^{31 32 34}	28/3437	23/3277	1.08 (0.56 to 2.06)			77	0.14
Clinically relevant bleeding
Dabigatran:
Hip^{20 22}	178/3367	87/2181		1.22 (0.95 to 1.58)		51.8	0.36
Knee^{19 21}	162/3141	79/1575		1.01 (0.74 to 1.39)		48.2	0.36
Rivaroxaban:
Hip^{23 24 27 29 30}	186/3888	152/3990		1.25 (0.90 to 1.75)		59.6	0.90
Knee^{25 26 28}	123/2940	96/2946		1.29 (0.99 to 1.67)		40.4	0.90
Apixaban:
Hip³³	131/2708	138/2699		0.95 (0.75 to 1.19)		52.2	0.09
Knee^{31 32 34}	103/3437	143/3277		0.71 (0.55 to 0.91)		47.8	0.09
Net clinical endpoint
Dabigatran:
Hip^{20 22}	81/3367	38/2181		1.26 (0.80 to 1.98)	49.3		0.06
Knee^{19 21}	58/3141	41/1575		0.71 (0.48 to 1.05)	50.7		0.06
Rivaroxaban:
Hip^{23 24 27 29 30}	86/3888	94/3990		0.92 (0.60 to 1.41)	53.2		0.76
Knee^{25 26 28}	71/2940	84/2946		0.85 (0.60 to 1.19)	46.8		0.76
Apixaban:
Hip³³	29/2708	29/2699		1.00 (0.60 to 1.66)	32.8		0.70
Knee^{31 32 34}	58/3437	62/3277		0.88 (0.62 to 1.26)	67.2		0.70

*Random effects model, subgroup differences.